Develops proprietary technology to convert skin cells into hair stem cells, creating personalized solutions for hair loss due to aging and baldness.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
dNovo is developing a proprietary direct reprogramming system to generate new, personalized hair stem cells to replace cells lost due to aging or conditions such as male patterned baldness. Using its proprietary technology, the company has converted human skin cells directly into induced hair stem cells without going through a pluripotent state.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
dNovo Management Team
dNovo Valuations & Financials
View real-time NPM data on dNovo stock including daily dNovo stock price estimates, valuation history, and historical share price information. Access dNovo financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track dNovo pricing across six independent market signals. Looking for private company due diligence data sources on dNovo? Get in touch to learn more.
Similar Companies
like dNovo
Conformal
Healthcare & Life Sciences
Focused on developing next-generation technology for left atrial appendage occlusion to reduce stroke risk.
Teon Therapeutics
Healthcare & Life Sciences
Reverses immune suppression in tumors by developing GPCR-targeted small molecules with combination immunotherapy potential.
Aardvark Therapeutics
Healthcare & Life Sciences
Developing oral therapies targeting gut-brain signaling to treat hunger-related disorders and metabolic diseases.
Mon Ami
Healthcare & Life Sciences
Simplifies human-services workflows by uniting client care, provider management and reporting into one solution.
CTRL Therapeutics
Healthcare & Life Sciences
Develops therapies which harness circulating tumor-reactive lymphocytes to treat solid cancers.
Accutar Biotech
Healthcare & Life Sciences
A biotechnology company that accelerates drug discovery using AI-powered computational design and wet lab validation.
Zuub
Healthcare & Life Sciences
Empowers dental practices with AI automation that simplifies insurance checks and streamlines treatment planning for clearer workflows.
Assort Health
Healthcare & Life Sciences
Develops AI-powered solutions that automate patient call management, enhancing efficiency and reducing wait times in healthcare settings.
ParaGen Technologies
Healthcare & Life Sciences
Provides specialty semiconductor materials that enable precision chip fabrication and enhanced device performance.
FAQ
We have answers
dNovo stock does not trade on public stock exchanges. dNovo stock is considered a private security and you need to be an accredited investor to trade shares. To invest in dNovo stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
dNovo Stock does not trade on public stock exchanges. In order to sell dNovo shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
dNovo does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view dNovo share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for dNovo stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell dNovo stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in dNovo stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
dNovo is a private company and has not had an IPO. There is currently no dNovo IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to dNovo IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
